Literature DB >> 3787089

Absence of IgA nephropathy in patients with ankylosing spondylitis.

A J Swaak, I Frankfort, R S Menon, J M Pekelharing, O Planten.   

Abstract

In 40 patients with ankylosing spondylitis (AS) no evidence for IgA nephropathy was obtained. This conclusion was based on the absence of hematuria and on the inability to find an increased incidence of IgA-containing immunoglobulin deposits in skin biopsies. Increased Clq binding assay was only found in those AS patients with anterior uveitis. In 26% of the skin biopsies perivascular mononuclear cell infiltrates were observed, and immunoglobulin deposits were seen in 65%. These facts suggest that the immunologic system is involved in the pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3787089     DOI: 10.1007/bf00541280

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  21 in total

1.  Isolated glomerulonephritis with mesangial IgA deposits.

Authors:  J G Sissons; D F Woodrow; J R Curtis; D J Evans; P E Gower; J C Sloper; D K Peters
Journal:  Br Med J       Date:  1975-09-13

2.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

Review 3.  The immunopathology of joint inflammation in rheumatoid arthritis.

Authors:  N J Zvaifler
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

4.  Serum ceruloplasmin concentration in rheumatoid arthritis, ankylosing spondylitis, psoriasis and sarcoidosis.

Authors:  P Koskelo; M Kekki; M Virkkunen; A Lassus; T Somer
Journal:  Acta Rheumatol Scand       Date:  1966

5.  Serum IgG, IgM, and IgA levels in ankylosing spondylitis.

Authors:  E M Veys; M van Leare
Journal:  Ann Rheum Dis       Date:  1973-11       Impact factor: 19.103

6.  Rheumatoid arthritis--the clinical significance of histo- and immunopathological abnormalities in normal skin.

Authors:  M L Westedt; C J Meijer; B J Vermeer; A Cats; E de Vries
Journal:  J Rheumatol       Date:  1984-08       Impact factor: 4.666

7.  A comparison of serum biochemistry in ankylosing spondylitis, seronegative and seropositive rheumatoid arthritis.

Authors:  J S Dixon; H A Bird; V Wright
Journal:  Ann Rheum Dis       Date:  1981-08       Impact factor: 19.103

8.  C-reactive protein, ESR, and klebsiella in ankylosing spondylitis.

Authors:  P Cowling; R Ebringer; D Cawdell; M Ishii; A Ebringer
Journal:  Ann Rheum Dis       Date:  1980-02       Impact factor: 19.103

9.  Secretory IgA: immune defence pattern in ankylosing spondylitis and klebsiella.

Authors:  M Calguneri; L Swinburne; R Shinebaum; E M Cooke; V Wright
Journal:  Ann Rheum Dis       Date:  1981-12       Impact factor: 19.103

10.  Correlation between levels of breakdown products of C3, C4, and properdin factor B in synovial fluids from patients with rheumatoid arthritis.

Authors:  L H Perrin; U E Nydegger; R H Zubler; P H Lambert; P A Miescher
Journal:  Arthritis Rheum       Date:  1977-03
View more
  4 in total

1.  Immunoglobulin A in the skin of patients with ankylosing spondylitis.

Authors:  A Collado; R Sanmarti; I Bielsa; T Castel; E Kanterewicz; J D Cañete; M A Brancós; J Rotes-Querol
Journal:  Ann Rheum Dis       Date:  1988-12       Impact factor: 19.103

2.  Absence of an association between ankylosing spondylitis and IgA nephropathy.

Authors:  M A van de Laar; H J Moens; J K van der Korst
Journal:  Ann Rheum Dis       Date:  1989-03       Impact factor: 19.103

3.  Microcirculation in ankylosing spondylitis.

Authors:  D Wendling; J C Risold
Journal:  Ann Rheum Dis       Date:  1994-04       Impact factor: 19.103

4.  Relation of microscopic haematuria in ankylosing spondylitis to circulating IgA containing immune complexes.

Authors:  A J Peeters; A W van den Wall Bake; A D van Dalsen; M L Westedt
Journal:  Ann Rheum Dis       Date:  1988-08       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.